Beauty Health finalizes separation with former CEO Stanleick; 58,536 shares vested, 18-month non-compete

SkinHealth Systems Inc.

CEO Andrew Stanleick terminated without cause effective Nov 19, 2023; signed Separation Letter on Dec 8, 2023.
Severance includes 18 months base salary, prorated target bonus, COBRA reimbursements, and outplacement up to $15,000.
Retention award of 58,536 shares of Class A common stock fully vested within 15 days of signing release.
18-month non-competition covenant barring work with microdermabrasion/hydrodermabrasion machine manufacturers.
Mutual non-disparagement agreed; Stanleick remains bound by existing confidentiality obligations.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Andrew Stanleick

Chief Executive Officer

SKIN · SkinHealth Systems Inc.

Filed: December 14, 2023, 6:59 PM ET

Mr. Stanleick’s termination from his position as Chief Executive Officer of the Company without cause

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Stanleick departed as Chief Executive Officer at SkinHealth Systems Inc..

Action: terminated without cause
Role: Chief Executive Officer

Exact text from the filing

Mr. Stanleick’s termination from his position as Chief Executive Officer of the Company without cause

View on SEC.gov

SkinHealth Systems Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-041578

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.